David E. Gilham

The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity

Fiona Thistlethwaite, David E. Gilham, Ryan D. Guest et al. · Cancer Immunology Immunotherapy · 2017 · 395 citations · Full text

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma

Susanne H.C. Baumeister, Joana Murad, Lillian Werner et al. · Cancer Immunology Research · 2018 · 317 citations · Full text

The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune Receptors

Ryan D. Guest, Robert E. Hawkins, Eleanor J. Cheadle et al. · Journal of Immunotherapy · 2005 · 304 citations

Extracellular Spacer Regions, T-regulatory Cell, Immunology +19

The Optimal Antigen Response of Chimeric Antigen Receptors Harboring the CD3ζ Transmembrane Domain Is Dependent upon Incorporation of the Receptor into the Endogenous TCR/CD3 Complex

John S. Bridgeman, Robert E. Hawkins, Steve Bagley et al. · The Journal of Immunology · 2010 · 259 citations

Adaptive Immune System, T-regulatory Cell, Immunology +21

Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival

Richard W. Griffiths, Eyad Elkord, David E. Gilham et al. · Cancer Immunology Immunotherapy · 2007 · 194 citations · Full text

Urology, Cancer Immunosurveillance, Genitourinary Cancer +8